Trials / Conditions / Pancreatic Polypeptide Tumor

Pancreatic Polypeptide Tumor

16 registered clinical trials studyying Pancreatic Polypeptide Tumor.

Status	Trial	Sponsor	Phase
Completed	Laser Tissue Welding - Distal Pancreatectomy Sealing Study NCT03147768	Laser Tissue Welding, Inc.	Phase 1
Completed	Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors NCT02259725	University of Southern California	Phase 2
Terminated	Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kid NCT02273752	Emory University	Phase 2
Withdrawn	Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors NCT02108782	Academic and Community Cancer Research United	Phase 2
Terminated	Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With S NCT02031536	ECOG-ACRIN Cancer Research Group	Phase 2
Active Not Recruiting	Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors NCT01824875	ECOG-ACRIN Cancer Research Group	Phase 2
Completed	Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors NCT01525082	Shaheen Shagufta	Phase 2
Completed	Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade N NCT01204476	National Cancer Institute (NCI)	Phase 1
Completed	Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258	University of Southern California	Phase 1
Completed	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Isl NCT01010126	National Cancer Institute (NCI)	Phase 2
Completed	Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer NCT00454363	National Cancer Institute (NCI)	Phase 2
Completed	Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors NCT00131911	National Cancer Institute (NCI)	Phase 2
Completed	Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors NCT00655655	Mayo Clinic	Phase 1
Terminated	Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors NCT00084461	National Cancer Institute (NCI)	Phase 2
Completed	Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors NCT00075439	National Cancer Institute (NCI)	Phase 2
Completed	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074	National Cancer Institute (NCI)	Phase 1